High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead has touted the potential of its liver disease drug in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication.
In late May 2026, Gilead Sciences reported new Phase 3 post hoc data showing that Livdelzi produced high, durable reductions in key liver markers for people with primary biliary cholangitis, while also securing accelerated U.S. approval for Hepcludex in chronic hepatitis delta and a positive EU opinion to broaden Trodelvy’s use in metastatic triple-negative breast cancer. These advances highlight how Gilead is consolidating its position in liver disease and oncology by deepening evidence for...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc analysis that showed that Livdelzi® was associated with high and sustained rates of normalization of a key liver marker in people living with primary biliary […]
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that GILD presented long-term interim findings from the ongoing Phase 3 ASSURE study of Livdelzi at the 2026 European Association for the Study […]
Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
The United States market has shown robust performance, rising 1.6% over the last week and surging 28% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks trading at significant discounts can offer potential opportunities for investors looking to capitalize on undervaluation relative to market growth expectations.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Safest Dividend Stocks to Buy Right Now. On May 21, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company, together with its subsidiary Kite, will present over 25 abstracts at the 2026 ASCO Annual Meeting (May 29 – June 2) and the EHA Congress (June 11 […]
The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.
Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
The United States market has shown robust growth, with a 1.8% increase over the last week and a remarkable 28% rise over the past year, while earnings are projected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future growth.
The United States market has shown robust performance, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying stocks that are trading below their estimated value can offer potential opportunities for investors looking to capitalize on market growth while minimizing risk.
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Stocks to Invest In. On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the […]
The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.
Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for HDV patients and the HDV market.
The United States market has shown robust performance, climbing 1.2% in the last week and 29% over the past year, with earnings projected to grow by 17% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.
The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ […]
Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market growth while considering intrinsic value.
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
The United States market has experienced a notable uptick, rising 1.1% over the last week and achieving a 29% increase over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of robust growth, identifying stocks that are potentially trading below their estimated fair value can offer investors opportunities to capitalize on undervalued assets with promising prospects.
With an annual dividend yield of 2.50%, Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. On May […]
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel
If you are wondering whether Gilead Sciences at US$134.36 is still offering value, the starting point is to understand what the current market price is implying about the business. The stock has returned 3.7% over the last 7 days, 1.1% over the last 30 days, 10.5% year to date, 28.5% over 1 year, 92.9% over 3 years and 144.9% over 5 years, which gives useful context for how expectations and perceived risk have shifted over time. Recent coverage has focused on Gilead Sciences as a large...
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the
U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.